Del 6 i serien Resistance to Targeted Anti-Cancer Therapeutics

Resistance to Immunotoxins in Cancer Therapy

Inbunden, Engelska, 2015

1 449 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Produktinformation

Utgivningsdatum2015-06-27
Mått155 x 235 x 21 mm
Vikt571 g
FormatInbunden
SpråkEngelska
SerieResistance to Targeted Anti-Cancer Therapeutics
Antal sidor249
Upplaga2015
FörlagSpringer International Publishing AG
ISBN9783319172743

Tillhör följande kategorier

Onkologi inom Medicin

Rama Shanker Verma, Ph.D., is Professor, Department of Biotechnology, the Indian Institute of Technology. Professor Verma specializes in the development of novel immunotoxins for cancer therapies. He has published 76 scientific articles, five book chapters, and several conference abstracts. He is an Elected Fellow, the Association of Microbiologists of India an Elected Fellow, the Society for Applied Biotechnology. He received the award for Excellence in Medical Biotechnology from the Society for Applied Biotechnology.

1 Targeted Cancer Therapy: History and Development of Immunotoxins.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins.-4 Cell Signaling and Resistance to Immunotoxins.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins .-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy .-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins.-9 Therapeutic Impact of Immune Responses in Cancer.